{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:07:43Z","timestamp":1774354063024,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microbiology and Immunology"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:label\/><jats:p>Secondary hypogammaglobulinemia is one of the factors responsible for the increased susceptibility to infection in patients with chronic lymphocytic leukemia (CLL). This study assessed the therapeutic results, concomitant medication and tolerance of administering 5% intravenous immunoglobulin, secondary immunodeficiency and recurrent serious bacterial infections. A single center, post\u2010marketing, observational clinical study was performed on 10 patients with a variety of hematological malignancies (CLL, follicular non\u2010Hodgkin lymphoma, IgM\u2010secreting immunocytoma, IgA plasmacytoma and myelodysplastic syndrome\/non\u2010Hodgkin lymphoma) who had been infused with IVIG from June 1994 to May 2009. The clinical benefit of IVIG was assessed by comparing the incidence of bacterial infections before and after starting this therapy. Plasma immunoglobulin concentrations and relevant hematological variables were recorded. For safety assessment, adverse events were monitored. The standard IVIG dosage was approximately 0.35\u2009g\/kg body weight every 3\u20134 weeks. Most patients had normal IgG trough values of\u2009&gt;600\u2009mg\/dL during the IVIG treatment period. The rate of bacterial infections was reduced from 2.4 per patient in the 3 months before IVIG to 0.7 (0\u20131.5) per patient per year during IVIG treatment. All patients received concomitant medication, mainly anticancer and anti\u2010anemia therapy (100%). No serious adverse events related to IVIG were observed. The frequency of at least one minor adverse reaction was 1.44% (8\/556 infusions). In conclusion, the investigated IVIG preparation was well tolerated and clinically beneficial in reducing the long term rate of serious bacterial infections in patients receiving concomitant treatment for malignant diseases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1348-0421.12060","type":"journal-article","created":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T11:57:36Z","timestamp":1366631856000},"page":"527-535","source":"Crossref","is-referenced-by-count":26,"title":["Post\u2010marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections"],"prefix":"10.1111","volume":"57","author":[{"given":"Georg","family":"G\u00fcnther","sequence":"first","affiliation":[{"name":"Medical Care Center for Blood and Cancer Diseases Potsdam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Dreger","sequence":"additional","affiliation":[{"name":"Medical Affairs Department Grifols Deutschland GmbH Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61125-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-317073"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2848"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_8_7_1","volume-title":"Clinical Applications of Intravenous Immunoglobulin Therapy","author":"Attard A.R.","year":"1992"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01874.x"},{"key":"e_1_2_8_9_1","unstructured":"The European Agency for the Evaluation of Medicinal Products. (2010) Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (EMA\/CHMP\/BPWP\/94038\/2007 rev. 3)."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90344-9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810063191403"},{"key":"e_1_2_8_12_1","unstructured":"EhningerG. JopskiB. DopferR. WahnU. GrehenJ. ZurbornK.H. (1994) Efficacy and safety of pasteurized intravenous 7S\u2010immunoglobulin in primary and secondary immune deficiencies: results of a multicenter trial.12th European Immunology Meeting BarcelonaAbstract W50\u201015:457."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1995.tb00322.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00918268"},{"key":"e_1_2_8_15_1","first-page":"17","article-title":"Intravenous immune globulin in chronic lymphocytic leukaemia","author":"Gamm H.","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_8_16_1","first-page":"121","article-title":"Prophylaxis against infections with low\u2010dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica S.","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_8_17_1","first-page":"1860","article-title":"Report of the Committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone P.P.","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_8_20_1","unstructured":"Instituto Grifols S.A. Flebogamma 5%: Summary of product characteristics available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000781\/WC500023473.pdf. Last accessed: October 29 2012."},{"key":"e_1_2_8_21_1","unstructured":"The European Agency for the Evaluation of Medicinal Products. (1999) Notice to Marketing Authorisation Holders. Pharmacovigilance Guidelines. CPMP\/PhVWP\/108\/99."},{"key":"e_1_2_8_22_1","volume-title":"Internal Medicine","author":"Herold G.","year":"2010"},{"key":"e_1_2_8_23_1","first-page":"1548","article-title":"Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values","volume":"351","author":"Kratz A.","year":"1993","journal-title":"N Engl J Med"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02834.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2004.11.010"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl141"},{"key":"e_1_2_8_27_1","unstructured":"US FDA. Guidance for Industry. Efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary immune deficiency. Last accessed: October 29 2012. FDA 29\u20106\u20100008; Available from URL:http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/blood\/ucm078526.pdf."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2008.06.002"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOCI.0000029108.18995.61"}],"container-title":["Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1348-0421.12060","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1348-0421.12060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T18:23:22Z","timestamp":1696530202000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1348-0421.12060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1111\/1348-0421.12060"],"URL":"https:\/\/doi.org\/10.1111\/1348-0421.12060","archive":["Portico"],"relation":{},"ISSN":["0385-5600","1348-0421"],"issn-type":[{"value":"0385-5600","type":"print"},{"value":"1348-0421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}